Document is current
Any future updates will be listed below
-
Authors
Koelzer, Viktor H. http://orcid.org/0000-0001-9206-4885
Sirinukunwattana, Korsuk
Rittscher, Jens
Mertz, Kirsten D.
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P2SKP3_168322/2)
Krebsliga Beider Basel (KLbB-4182-03-2017)
Freiwillige Akademische Gesellschaft Basel
- License Information
-
More Information
Article History
Received: 15 May 2018
Revised: 6 November 2018
Accepted: 9 November 2018
First Online: 23 November 2018
Compliance with ethical standards
: No research involving human participants and/or animals was performed for this study.
: KS and JR have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents received or pending. V.H.K. and K.D.M. are participants of a patent application co-owned by the Netherlands Cancer Institute (NKI-AVL) and the University of Basel on the assessment of cancer immunotherapy biomarkers by digital pathology. Based on NKI-AVL and the University of Basel policy on management of intellectual property, V.H.K. and K.D.M. would be entitled to a portion of received royalty income. V.H.K. has served as an invited speaker on behalf of Indica Labs.
